Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

This study, building on the lessons learned from the ADAPT Study; will further investigate the effectiveness and safety of a combination pharmacotherapy (XR-NTX; as Vivitrol® plus once-daily bupropion extended-release tablets) for methamphetamine use disorder.

CTN Protocol ID:

CTN-0068

ClinicalTrials.gov ID:

NCT03078075

Principal Investigator(s)

Madhukar H. Trivedi, M.D.
Betty Jo Hay Distinguished Chair in Mental Health Professor, Node Principal Investigator
University of Texas Southwestern Medical Center
Department of Psychiatry
5323 Harry Hines Boulevard
Dallas, TX 75390
United States
madhukar.trivedi@utsouthwestern.edu